Company
Business
Stem Cell Therapy
Organoid
CDMO Business
2025
12Signed a joint research agreement with the Institut Pasteur Korea for hair follicle organoid screening
07Registered a U.S. patent for combination therapy technology for knee osteoarthritis
04Presented Phase 1 clinical trial results for “OSCA” at the Osteoarthritis Research Society International (OARSI) World Congress
03Initiated Phase 2a clinical trial of the osteoarthritis therapy “OSCA” with the first patient dosing
02Received final approval from Japan’s Ministry of Health, Labour and Welfare for regenerative medicine using adipose-derived stem cells
2024
11Signed a license-out agreement with Yooyoung Pharma for the osteoarthritis therapy “OSCA”
07Announced topline results from the Phase 3 clinical trial of “Furestem-AD Inj.” for atopic dermatitis
05Signed an MOU with HLB bioStep for organoid-based research and development
04Received approval from the Ministry of Food and Drug Safety for the therapeutic use of “Furestem-AD Inj.” For atopic dermatitis
01GMP Center received approval from Japan’s Ministry of Health, Labour and Welfare as a recognized manufacturer of specified processed cells
2023
11Registered a Chinese patent for specialized cell therapy technology with enhanced immunomodulatory capabilities
08Initiated Phase 1 clinical trial of the osteoarthritis therapy “Furestem-OA Kit Inj.” with the first patient dosing
05Presented results for the osteoarthritis therapy “Furestem-OA Kit Inj.” at the International Congress of Orthopaedics (ATiO)
02Signed an MOU with P&K Skin Research Center to develop a skin organoid–based efficacy evaluation platform
2022
09Published, in collaboration with Seoul National University, the world’s first skin organoid that fully replicates human skin and hair follicles in an international scientific journal
07Registered a European patent for a stem cell–based combination therapy for osteoarthritis
05Signed an MOU with Kangwon National University Hospital for research collaboration in advanced regenerative medicine
04Signed a CDMO agreement with YJ Cerapeutics
2021
07Granted a license for the management of human cells etc.
05Approval of IND application for Phase 3 clinical trial of Furestem-AD inj by MFDS
04Entered into MOU with Seoul National University Bundang Hospital
02Acquisition of cosmetics business
2020
12Obtained a manufacturing license from MFDS for advanced biopharmaceuticals
04Signed MOU for gene and cell therapy research with G+FLAS Life Sciences
2019
03Signed exclusive rights for domestic sales of Furestem-AD and technology transfer agreement with HYUNDAI Bioland
2018
02Received IND approval for Phase 1/2a clinical trial of Furestem-RA from MFDS
2017
09Signed Joint Development Agreement with Germany’s Heraeus Medical GmbH for osteoarthritis stem cell therapy
2016
10Nominated for Korea-China Science Technology Collaboration Project – Researching stem cell therapy for neurological disorders targeted for Asians
10Nominated by The Ministry of Trade, Industry and Energy as a "K-BrainPower" company
02Signed stem cell conditioned media joint business contract with Dongwha Pharmaceutical (MOU)
2015
12Listed on KOSDAQ
08Concluded the contract of iNSC technology joint business with Orig3n of the U.S
08Expanded the Construction of Stem Cell GMP Center
08Selected for the business in the development of high tech medical technology – Phases 1/2a clinical research for Crohn’ disease
07Acquired ISO certificates (ISO 9001, ISO 14001)
06Selected for the future industry leading technology development business – R&D for cell culture system
01Concluded the joint business contract for the stem cell conditioned medium cosmetics with COSON.
2014
12Approved of Furestem-CD® Phase 1 (added psoriasis indicant)
12Concluded a contract for the stem cell therapy sales right and joint development with Daewoong Pharmaceutical Inc
09Selected for the high tech medical technology development business – Occlusive arteriopathy preclinical
06Certified for Technology INNO-BIZ
05Approved of Furestem-RA® Phase 1
2013
12Changed business name to Kangstem Biotech
10Selected for the parts material business – GvHD preclinical
06Approved of Furestem-CD® Phases 1 & 2a
01Approved of Furestem-AD® Phases 1 & 2a
2012
12Selected for the public health medical research development business - Psoriasis preclinical
05Selected for the public health medical study development business - Crohn’s disease preclinical
02Completed the construction of Stem Cell GMP Center
2011
12Selected for the industry & academy cooperative technology transfer business – Atopic Dermatitis preclinical
08Recognized for the company auxiliary research center by KOITA (Korea Industry & Technology Association)
02Certified for the venture company by KIBO (Korea Technology Finance Corporation)
2010
10Established Kangstem Holdings